(NU/1257) Clinical Trial Unit or Contracted Research Organisation to set up and manage Vision DMD Phase 2b and extension study
NEWCASTLE UNIVERSITY · £640,000 – £800,000 · closes 22 Mar 2017
£640,000 – £800,000
Estimated value
Closed
Deadline
20 Feb 2017
Published
This tender has closed.
See what's open in research and development, or get contracts like this in your inbox each morning — free.
About this contract
This is an EU Open Tender. The scope of this contract relates specifically to the Phase 2b Randomized, Double-blind, Parallel Placebo- and Active-controlled Study to Assess the Efficacy and Safety of Vamorolone in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) and the extension study that will follow this. A registered Clinical Trial Unit (CTU) or Contracted Research Organisation (CRO) is required to set up and manage the clinical trial at sites in [UK/Australia/Israel/Sweden]. The CTU / CRO will be carrying out delegated duties on behalf of the sponsor, ReveraGen, but will be receiving payments for these duties from the Vision-DMD Horizon 2020 grant, coordinated by Newcastle University. This contract consists of 4 separate geographical Lots: Lot 1: UK Lot 2: Australia Lot 3: Israel Lot 4: Sweden
Key dates
Source
Who to contact
Tender documents
Similar open tenders
Contains public sector information licensed under OGL v3.0